YIH
PTCT icon

Y-Intercept (HK)’s PTC Therapeutics PTCT Stock Holding History

Y-Intercept (HK)’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-21,889
Closed -$1.34M – 1912
2025
Q3 		$1.34M Sell
21,889
-5,943
-21% -$310K 0.03% 828
2025
Q2 		$1.36M Buy
27,832
+22,851
+459% +$1.08M 0.03% 791
2025
Q1 		$254K Sell
4,981
-6,043
-55% -$302K 0.02% 956
2024
Q4 		$498K Sell
11,024
-2,805
-20% -$120K 0.03% 731
2024
Q3 		$513K Sell
13,829
-18,312
-57% -$613K 0.03% 763
2024
Q2 		$983K Buy
32,141
+5,185
+19% +$168K 0.05% 499
2024
Q1 		$784K Buy
+26,956
New +$755K 0.06% 490
2023
Q2 		– Sell
-7,739
Closed -$375K – 1633
2023
Q1 		$375K Buy
+7,739
New +$354K 0.04% 668
2021
Q1 		– Sell
-4,376
Closed -$267K – 765
2020
Q4 		$267K Buy
+4,376
New +$258K 0.11% 350

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Y-Intercept (HK)'s PTCT Position: Q4 2025 in Review

Y-Intercept (HK) sold out of PTC Therapeutics (PTCT) in Q4 2025, closing a stake of 21,889 shares — an estimated $1.34M sold.

Y-Intercept (HK) first reported a position in PTCT in Q4 2020 and held it in 9 quarters. The position peaked at $1.36M in Q2 2025. 353 funds tracked by Wall St. Rank hold PTCT as of Q4 2025.

  • Y-Intercept (HK) reported no remaining PTC Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Y-Intercept (HK) sold 21,889 PTC Therapeutics shares in Q4 2025, an estimated $1.34M.
  • Y-Intercept (HK) first reported a position in PTC Therapeutics in Q4 2020 and held it in 9 quarters.
  • Y-Intercept (HK)'s PTC Therapeutics position peaked at $1.36M in Q2 2025.
  • 353 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2025.

Based on Y-Intercept (HK)'s 13F filing for Q4 2025, filed 13 Feb 2026.